Skip to content
Aminoscope
← Research
GLP-1

Retatrutide side effects: Phase 2 and published Phase 3 evidence

Dose-related gastrointestinal events dominate, with a transient glucagon-linked rise in heart rate — with published Phase 3 evidence now available. No long-term safety data, no approved product, and gray-market risk on top.

Priya Anand6 min read
Retatrutide adverse events climb with dose: the Phase 2 gastrointestinal signalGastrointestinal adverse eventsnausea · vomiting · diarrhea · constipation1 mg4 mg8 mg12 mghigher maintenance dose →GI EVENTS CLIMB WITH DOSE · PHASE 2
Need a closer look?Enlarge illustration

Retatrutide has produced the largest weight-loss numbers yet reported for a drug — the efficacy side is laid out in our clinical evidence monograph. This page is the other half of that ledger: what the same trials reported about harm. The honest framing first — retatrutide is investigational, still in Phase 3, and the historical table below describes Phase 2, with a separate published Phase 3 update. It is a real drug with a real, dose-related side-effect profile, not a benign peptide.

The dominant signal: gastrointestinal events

Like every incretin-based agent, retatrutide’s most common adverse effects were gastrointestinal. In the 48-week Phase 2 obesity trial, nausea, diarrhea, vomiting and constipation were the most frequently reported events, they were mostly mild to moderate, and they were dose-related — more common at the higher maintenance doses and concentrated during the dose-escalation period.[1] The parallel Phase 2 trial in adults with type 2 diabetes put numbers on the same pattern: mild-to-moderate gastrointestinal events in 67 of 190 participants on retatrutide (35%) against 6 of 45 on placebo (13%), climbing with dose from 13% in the 0.5 mg group to 50% in the fastest 8 mg escalation arm.[2] This is why escalation schedule matters, and it is covered in our dosage page and in the broader GLP-1 GI side-effect timeline.

Swipe to see all columns

Retatrutide's Phase 2 adverse-event profile. Gastrointestinal events dominate and track with dose; the heart-rate rise is the glucagon-linked signal.
Adverse effectWhat the Phase 2 trials foundTrial
NauseaMost common; mild–moderate; dose-relatedObesity + T2D
DiarrheaCommon; dose-relatedObesity + T2D
VomitingCommon; more frequent at higher dosesObesity + T2D
ConstipationReported among the leading GI eventsObesity
Heart-rate increaseDose-dependent; peaked ≈ week 24, then declinedObesity
Retatrutide's Phase 2 adverse-event profile. Gastrointestinal events dominate and track with dose; the heart-rate rise is the glucagon-linked signal. PMIDs 37366315 (obesity), 37385280 (type 2 diabetes)

The glucagon consideration: heart rate

The third receptor is what sets retatrutide apart, and it carries its own signal. In the obesity trial, mean heart rate rose in a dose-dependent way, peaked at around week 24, and then declined toward week 48 — a transient pattern rather than a steady climb.[1] Glucagon-receptor agonism raising heart rate is mechanistically expected, and it is precisely the kind of cardiometabolic effect that a mid-stage trial can describe but cannot adjudicate for long-term safety.

What we simply don’t know yet

The largest caveat is limited long-term exposure and outcomes evidence. There are no multi-year exposure results, no completed cardiovascular or renal outcomes results established here, and no post-marketing surveillance — because there is no market. The detailed adverse-event tables on this page are still a Phase 2 read-out, while published Phase 3 adds a larger study population. Rare or delayed adverse effects, by definition, do not show up reliably in trials of this size and duration; that is what the completed Phase 3 program and any eventual FDA review exist to establish. How retatrutide’s tolerability is likely to compare against the approved dual agonist is discussed in our retatrutide versus tirzepatide comparison — but even there, cross-trial safety comparisons are suggestive, not definitive.

The gray-market problem sits on top of all of this

Because retatrutide is not approved, supply requires a clinical trial or an authorized access pathway. Anything sold as “research” retatrutide is unregulated, and it adds a second layer of risk that has nothing to do with the molecule’s own adverse events: unknown purity, possible contamination, and unverifiable dosing. The trial data above describe a specific compound given at controlled doses under medical supervision. None of those conditions hold for material bought online, so the Phase 2 safety profile cannot be assumed to transfer to it. This page is not a self-use guide.

The honest bottom line

Retatrutide’s side-effect story is, so far, a familiar incretin one told at a new intensity: dose-related gastrointestinal events as the dominant burden, plus a transient glucagon-linked rise in heart rate.[1][2] None of that is disqualifying — it is roughly what the class predicts — and the drug remains investigational. There is no long-term safety record, no approved product, and no approved retail product. The appropriate posture is to watch the Phase 3 data as it arrives and to treat any decision as one for a clinician, not a forum. Until it reaches US pharmacies, the weight-loss drugs you can actually be prescribed are semaglutide and tirzepatide; the Eden review covers a service offering both compounded and branded versions.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. PMID 37366315
  2. [2] Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. PMID 37385280
  3. [3] Eli Lilly and Company. (2026). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results, including adverse-event rates at the 12 mg dose). investor.lilly.com (news release, May 21, 2026). Source
  4. [4] Jastreboff AM, Kaplan LM, Davies MJ, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. PMID 42814954
  5. [5] Eli Lilly and Company (2026). Expanded access — eligibility, physician requests and regulatory permission. Lilly. Source

Where to get it

Compare GLP-1 providers

See where to actually get semaglutide or tirzepatide — branded, compounded and cash-pay — compared on transparency, care, and price.

Compare providers →

Related tool

GLP-1 weight-loss comparison

See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.

More in GLP-1